Clinical trials: sponsored by GC Biopharma Corp
- Lead sponsor (exact) GC Biopharma Corp
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Influenza A, Influenza B, Influenza Vaccination
Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older
This is a multicenter, randomized, double-blind, active-controlled, parallel-group clinical trial in adults aged 65 years or older.
- Trial name
- GC3114B (NCT07883928)
- Testing
- vaccination of GC3114B, Vaccination of Efluelda
- Where
- South Korea
- Volunteers
- 1,806 people, healthy volunteers welcome
- Sponsor
- GC Biopharma Corp
COVID - 19
A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults
A Phase 1, Randomized, Double-blind, Dose-Escalation, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to 64 Years
- Trial name
- NCT07728396
- Testing
- GC4006A, Normal Saline
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GC Biopharma Corp
Varicella (Chickenpox), Chickenpox Vaccine
A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
This clinical study aims to evaluate the safety and immune response of MG1111, in healthy children compared to VARIVAX. The study will follow participants for 42 days after receiving two doses, with additional follow-ups for up…
- Trial name
- NCT07054099
- Testing
- MG1111 (Barycela inj.), VARIVAX™
- Where
- Thailand
- Volunteers
- 474 people, healthy volunteers welcome
- Sponsor
- GC Biopharma Corp
Tetanus-diphtheria-acellular Pertussis (Tdap)
A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults
This clinical trial consists of two parts: Part 1, which explores safety, and Part 2, which examines both safety and efficacy (immunogenicity).
- Trial name
- NCT06997627
- Testing
- GC3111B, Boostrix®
- Where
- South Korea
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GC Biopharma Corp
Healthy Volunteers
A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions
The purpose of this study is to evaluate the safety and pharmacokinetics of oral administration of GC2129A in fed conditions to healthy adult volunteers.
- Trial name
- NCT05729386
- Testing
- GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2)
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GC Biopharma Corp
Healthy Volunteers
A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions
The purpose of this study is to evaluate the safety and pharmacokinetics of oral administration of GC2129A in fasting conditions to healthy adult volunteers.
- Trial name
- NCT05703984
- Testing
- GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2)
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GC Biopharma Corp
Varicella Zoster Virus Infection
An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years
The goal of this bridging study is to assess the safety and immunogenicity of BARYCELA inj. in healthy Vietnamese children aged between 12 months to 12 years. The main questions it aims to answer are: Safety of BARYCELA inj.
- Trial name
- NCT05664152
- Testing
- MG1111
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- GC Biopharma Corp